Help & Feedback

How have you calculated the data for risk & benefit visualizations?

Risk and benefit visualizations rely on data from individual clinical trials or meta-analyses.
 
When data is based on an individual clinical trial, we visualize particular efficacy or safety data by converting the % of study patients experiencing a benefit or risk into an absolute benefit/risk to 1,000 and 10,000 people. We are visualizing this data compared to placebo, except where stated, so the charts only show the treatment effect. We may look to include the benefit/risk from placebo and/or natural course of disease in future.
 
When the visualization is based on a meta-analysis, we will have converted either a number needed to treat (NNT) or an absolute risk reduction (ARR) into an absolute benefit/risk to 1,000 and 10,000 people. Many meta-analyses only provide relative risk data between two treatments, in which case we would not include this data in our visualization.

Terms and conditions

By using this site you acknowledge that the content of this website is based on a review process of the ECCO Consensus Guidelines and primarily aims at facilitating their visualization.

Any treatment decisions are a matter for individual clinicians and may not be based primarily on the e-Guide content.

The European Crohn's and Colitis Organisation and/or any of its staff members and/or any website contributor may not be held liable for any information published in good faith on this website.

You agree that the use of this website is at your own risk and hereby waive any and all potential claims against European Crohn's and Colitis Organisation, and/or any of its staff members and/or any of the website contributors.